Lakewood-Amedex Supports Reintroduction of PASTEUR Act
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 21 hours ago
0mins
Lakewood-Amedex Biotherapeutics announced its support for the reintroduction of the bipartisan Pioneering Antimicrobial Subscriptions to End Upsurging Resistance, PASTEUR, Act, legislation designed to "encourage" the development of novel therapies to address the growing global threat of antimicrobial resistance. "Antimicrobial resistance is rapidly becoming one of the greatest threats to global healthcare, making the development of novel anti-infective therapies more important than ever," said Kelvin Cooper, Ph.D., Chief Executive Officer of Lakewood-Amedex Biotherapeutics. "The reintroduction of the PASTEUR Act recognizes the urgent need for innovation in this critically important field. At Lakewood-Amedex Biotherapeutics, we believe our proprietary Bisphosphocin platform represents exactly the type of differentiated antimicrobial technology needed to help address resistant microbial infections, and we look forward to advancing the development of Nu-3 in patients with infected diabetic foot ulcers."
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy LABT?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on LABT
Wall Street analysts forecast LABT stock price to rise
0 Analyst Rating
0 Buy
0 Hold
0 Sell
Current: 2.740
Low
Averages
High
Current: 2.740
Low
Averages
High
No data
About LABT
Lakewood-amedex Biotherapeutics Inc is a pharmaceutical company. The Company is focused on addressing unmet needs in the treatment of serious infectious diseases, improving patient outcomes, and significantly reducing the threat posed by antibiotic-resistant bacterial strains like MRSA, NDM-1, and many others. The Company is engaged in development of its Bisphosphocin class of antimicrobial agents. The Company is exploring additional local drug delivery applications, including complicated urinary tract infections (CAUTI) and pulmonary infections. The Company has a portfolio of compounds that are being profiled for indications such as infected diabetic foot ulcer, urinary tract infections, and pulmonary infections.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Lakewood-Amedex Unveils New Antimicrobial Platform
- Innovative Antimicrobial Platform: Lakewood-Amedex Biotherapeutics has launched its proprietary Bisphosphocin® platform, designed to rapidly and effectively combat microbial infections, particularly antibiotic-resistant bacteria, demonstrating high efficacy against MRSA and VRE in vitro while potentially lowering the risk of resistance development.
- Legislative Support: The company supports the reintroduction of the PASTEUR Act, aimed at encouraging the development of novel therapies to address the global threat of antimicrobial resistance, reflecting the urgent need for innovative anti-infective solutions and furthering the company's strategic positioning in this critical field.
- Clinical Development Progress: Lakewood-Amedex is preparing to enter Phase 2 clinical development for its lead product candidate Nu-3, targeting infected diabetic foot ulcers (iDFUs), a significant unmet medical need affecting millions worldwide, often leading to hospitalization and amputation if not controlled early.
- Market Potential: With the emergence of antibiotic-resistant pathogens, the importance of Nu-3 as an innovative therapeutic option is increasingly highlighted, expected to provide substantial market opportunities for the company, particularly in controlling early-stage infections.
See More
Virtual Investor Conferences Forum Highlights
- On-Demand Presentations: The Life Sciences Virtual Investor Forum held on June 24-25, 2026, is now available for on-demand viewing for 90 days, enhancing investor engagement and understanding of participating companies.
- Company Participation: Companies such as MetaVia Inc. (NASDAQ: MTVA) and CytoSorbents Corporation (NASDAQ: CTSO) are accepting one-on-one management meeting requests, facilitating direct communication between investors and management teams.
- Investor Materials Access: Attendees can download investor materials from the companies' resource sections, which not only increases transparency but also provides potential investors with essential decision-making support.
- Interactive Platform Benefits: Virtual Investor Conferences offer real-time investor engagement solutions that replicate the components of on-site conferences, improving the efficiency of connections between companies and investors, thereby fostering stronger investor relations.
See More
Lakewood-Amedex Appoints New Scientific Advisor for iDFU Program
- Clinical Trial Leadership: Lakewood-Amedex Biotherapeutics has appointed Dr. David G. Armstrong as Study Chair for its Phase 2a clinical trial, which evaluates Nu-3 for infected diabetic foot ulcers, expected to provide crucial guidance for the company's innovations in antimicrobial therapies.
- Scientific Advisor Role: Dr. Armstrong will also serve as a Scientific Advisor for the iDFU program, leveraging his extensive experience in diabetic foot care and infection control to enhance the quality of Nu-3's clinical evaluation, thereby advancing the development of new therapeutic approaches.
- Clinical Trial Design: The Phase 2a trial will assess three concentrations of Nu-3 (2%, 5%, and 10%) to validate its safety and efficacy, laying the groundwork for a larger Phase 2b clinical study and addressing a significant treatment gap in diabetic foot infections.
- Antibiotic Resistance Challenge: Dr. Armstrong highlighted that infected diabetic foot ulcers pose a major clinical challenge, with antibiotic resistance necessitating new therapeutic strategies; the development of Nu-3 could provide patients with new treatment options and improve clinical outcomes.
See More
Agenda Announced for Life Sciences Virtual Investor Forum
- Forum Schedule: The Life Sciences Virtual Investor Forum, taking place on June 24-25, 2026, will bring together innovators from various companies, providing an efficient platform for direct engagement between investors and companies, expected to attract numerous individual and institutional investors.
- Easy Participation: Investors can register for free and run an online system check to expedite participation and receive event updates, with live company presentations and one-on-one meeting arrangements enhancing the investor experience during the forum.
- Company Showcase: The forum will feature multiple publicly traded companies, including MetaVia Inc. and CytoSorbents Corporation, covering various life sciences sectors, which is expected to provide investors with rich industry insights and investment opportunities.
- Investor Relations Enhancement: Virtual Investor Conferences aim to improve communication efficiency between companies and investors by offering real-time interactive engagement solutions, helping companies better showcase their strategies and business development plans.
See More
New Patent Expands Global IP Footprint
- Patent Portfolio Expansion: Lakewood-Amedex Biotherapeutics has secured a new patent in Australia protecting its Bisphosphocin® compounds, which target various antimicrobial infections such as complicated urinary tract infections and pulmonary infections, thereby strengthening the company's intellectual property foundation in the global antimicrobial sector.
- Global Reach Enhancement: The company currently holds 72 granted patents and 29 pending patents across multiple countries and regions, including the United States, Europe, and China, showcasing its extensive positioning and market potential in the development of antimicrobial drugs.
- Addressing Resistance Crisis: CEO Kelvin Cooper highlighted that antimicrobial resistance causes over six million deaths annually, and the new patent acquisition will aid the company in developing innovative solutions to meet the urgent needs of patients worldwide.
- Shareholder Value Creation: By bolstering its intellectual property base, Lakewood-Amedex Biotherapeutics not only enhances its competitive edge in the market but also has the potential to generate long-term value for shareholders, driving the company's ongoing growth in the antimicrobial field.
See More
New Patent Expands Global IP Footprint
- Patent Portfolio Expansion: Lakewood-Amedex Biotherapeutics has secured a new patent in Australia protecting Bisphosphocin® compounds for various antimicrobial infections, including complicated urinary tract infections and pulmonary infections, thereby strengthening its intellectual property foundation and enhancing market competitiveness.
- Global IP Strategy: The company currently holds 72 granted patents and 29 pending patents across multiple countries and regions, including the United States and Europe, showcasing its significant influence and market potential in the global antimicrobial sector.
- Addressing Antibiotic Resistance: CEO Kelvin Cooper highlighted that antimicrobial resistance causes over six million deaths annually, and the new patent will aid in developing innovative antimicrobial solutions to meet the urgent needs of patients worldwide.
- Enhancing Shareholder Value: By bolstering its intellectual property base, Lakewood-Amedex Biotherapeutics is positioned not only to effectively tackle the challenges of antimicrobial resistance but also to potentially create greater value for shareholders, driving long-term growth for the company.
See More
Lakewood-Amedex Unveils New Antimicrobial Platform
- Innovative Antimicrobial Platform: Lakewood-Amedex Biotherapeutics has launched its proprietary Bisphosphocin® platform, designed to rapidly and effectively combat microbial infections, particularly antibiotic-resistant bacteria, demonstrating high efficacy against MRSA and VRE in vitro while potentially lowering the risk of resistance development.
- Legislative Support: The company supports the reintroduction of the PASTEUR Act, aimed at encouraging the development of novel therapies to address the global threat of antimicrobial resistance, reflecting the urgent need for innovative anti-infective solutions and furthering the company's strategic positioning in this critical field.
- Clinical Development Progress: Lakewood-Amedex is preparing to enter Phase 2 clinical development for its lead product candidate Nu-3, targeting infected diabetic foot ulcers (iDFUs), a significant unmet medical need affecting millions worldwide, often leading to hospitalization and amputation if not controlled early.
- Market Potential: With the emergence of antibiotic-resistant pathogens, the importance of Nu-3 as an innovative therapeutic option is increasingly highlighted, expected to provide substantial market opportunities for the company, particularly in controlling early-stage infections.
See More
Virtual Investor Conferences Forum Highlights
- On-Demand Presentations: The Life Sciences Virtual Investor Forum held on June 24-25, 2026, is now available for on-demand viewing for 90 days, enhancing investor engagement and understanding of participating companies.
- Company Participation: Companies such as MetaVia Inc. (NASDAQ: MTVA) and CytoSorbents Corporation (NASDAQ: CTSO) are accepting one-on-one management meeting requests, facilitating direct communication between investors and management teams.
- Investor Materials Access: Attendees can download investor materials from the companies' resource sections, which not only increases transparency but also provides potential investors with essential decision-making support.
- Interactive Platform Benefits: Virtual Investor Conferences offer real-time investor engagement solutions that replicate the components of on-site conferences, improving the efficiency of connections between companies and investors, thereby fostering stronger investor relations.
See More
Lakewood-Amedex Appoints New Scientific Advisor for iDFU Program
- Clinical Trial Leadership: Lakewood-Amedex Biotherapeutics has appointed Dr. David G. Armstrong as Study Chair for its Phase 2a clinical trial, which evaluates Nu-3 for infected diabetic foot ulcers, expected to provide crucial guidance for the company's innovations in antimicrobial therapies.
- Scientific Advisor Role: Dr. Armstrong will also serve as a Scientific Advisor for the iDFU program, leveraging his extensive experience in diabetic foot care and infection control to enhance the quality of Nu-3's clinical evaluation, thereby advancing the development of new therapeutic approaches.
- Clinical Trial Design: The Phase 2a trial will assess three concentrations of Nu-3 (2%, 5%, and 10%) to validate its safety and efficacy, laying the groundwork for a larger Phase 2b clinical study and addressing a significant treatment gap in diabetic foot infections.
- Antibiotic Resistance Challenge: Dr. Armstrong highlighted that infected diabetic foot ulcers pose a major clinical challenge, with antibiotic resistance necessitating new therapeutic strategies; the development of Nu-3 could provide patients with new treatment options and improve clinical outcomes.
See More
Agenda Announced for Life Sciences Virtual Investor Forum
- Forum Schedule: The Life Sciences Virtual Investor Forum, taking place on June 24-25, 2026, will bring together innovators from various companies, providing an efficient platform for direct engagement between investors and companies, expected to attract numerous individual and institutional investors.
- Easy Participation: Investors can register for free and run an online system check to expedite participation and receive event updates, with live company presentations and one-on-one meeting arrangements enhancing the investor experience during the forum.
- Company Showcase: The forum will feature multiple publicly traded companies, including MetaVia Inc. and CytoSorbents Corporation, covering various life sciences sectors, which is expected to provide investors with rich industry insights and investment opportunities.
- Investor Relations Enhancement: Virtual Investor Conferences aim to improve communication efficiency between companies and investors by offering real-time interactive engagement solutions, helping companies better showcase their strategies and business development plans.
See More
New Patent Expands Global IP Footprint
- Patent Portfolio Expansion: Lakewood-Amedex Biotherapeutics has secured a new patent in Australia protecting its Bisphosphocin® compounds, which target various antimicrobial infections such as complicated urinary tract infections and pulmonary infections, thereby strengthening the company's intellectual property foundation in the global antimicrobial sector.
- Global Reach Enhancement: The company currently holds 72 granted patents and 29 pending patents across multiple countries and regions, including the United States, Europe, and China, showcasing its extensive positioning and market potential in the development of antimicrobial drugs.
- Addressing Resistance Crisis: CEO Kelvin Cooper highlighted that antimicrobial resistance causes over six million deaths annually, and the new patent acquisition will aid the company in developing innovative solutions to meet the urgent needs of patients worldwide.
- Shareholder Value Creation: By bolstering its intellectual property base, Lakewood-Amedex Biotherapeutics not only enhances its competitive edge in the market but also has the potential to generate long-term value for shareholders, driving the company's ongoing growth in the antimicrobial field.
See More
New Patent Expands Global IP Footprint
- Patent Portfolio Expansion: Lakewood-Amedex Biotherapeutics has secured a new patent in Australia protecting Bisphosphocin® compounds for various antimicrobial infections, including complicated urinary tract infections and pulmonary infections, thereby strengthening its intellectual property foundation and enhancing market competitiveness.
- Global IP Strategy: The company currently holds 72 granted patents and 29 pending patents across multiple countries and regions, including the United States and Europe, showcasing its significant influence and market potential in the global antimicrobial sector.
- Addressing Antibiotic Resistance: CEO Kelvin Cooper highlighted that antimicrobial resistance causes over six million deaths annually, and the new patent will aid in developing innovative antimicrobial solutions to meet the urgent needs of patients worldwide.
- Enhancing Shareholder Value: By bolstering its intellectual property base, Lakewood-Amedex Biotherapeutics is positioned not only to effectively tackle the challenges of antimicrobial resistance but also to potentially create greater value for shareholders, driving long-term growth for the company.
See More
